## **Table of Contents**

State/Territory Name: California

State Plan Amendment (SPA) #: 23-0044

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

## DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Medicare & Medicaid Services 601 E. 12th St., Room 355 Kansas City, Missouri 64106



Medicaid and CHIP Operations Group

January 22, 2024

Michelle Baass Director and Interim State Medicaid Director California Department of Health Care Services P.O. Box 997413, MS 0000 Sacramento, CA 95899-7413

Re: California State Plan Amendment (SPA) 23-0044

## Dear Director Baass:

The Centers for Medicare & Medicaid Services (CMS) reviewed your Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 23-0044. This amendment proposes to expand the prescribing authority for enteral formulae from physicians to include physicians, nurse practitioners, clinical nurse specialists, or physician assistants.

We conducted our review of your submittal according to statutory requirements in Title XIX of the Social Security Act and implementing regulations at 42 Code of Federal Regulations (CFR) 440.70. This letter is to inform you that California Medicaid SPA 23-0044 was approved on January 22, 2024, with an effective date of October 1, 2023.

If you have any questions, please contact Cheryl Young at 415-744-3598 or via email at Cheryl Young@cms.hhs.gov.

Sincerely,

Digitally signed by James G. Scott -S
Date: 2024.01.22
17:44:09 -06'00'

James G. Scott, Director Division of Program Operations

Enclosures

CENTERS FOR MEDICARE & MEDICAID SERVICES	OND NO. 0330-015.	
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	1. TRANSMITTAL NUMBER  2 3 — 0 0 4 4 CA  3. PROGRAM IDENTIFICATION: TITLE OF THE SOCIAL SECURITY ACT  XIX  XXI	
TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES	4. PROPOSED EFFECTIVE DATE October 1, 2023	
5. FEDERAL STATUTE/REGULATION CITATION 42 CFR §440.420 <sup>70</sup>	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a. FFY 2024 \$ 0 b. FFY 2025 \$ 0	
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Limitations on Attachment 3.1-A, page 14a <u>Limitations on Attachment 3.1-B, page 14a</u>	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable) Limitations on Attachment 3.1-A, page 14a Limitations on Attachment 3.1-B, page 14a	
9. SUBJECT OF AMENDMENT  To expand the prescribing authority for enteral formulae, when sup non-physician prescriber types	plied by a pharmacy provider, to include physician and	
10. GOVERNOR'S REVIEW (Check One)  GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED:  Please note: The Governor's Office does not wish to review the State Plan Amendment.	
12 TYPED NAME	15. RETURN TO Department of Health Care Services Attn: Director's Office	
Michelle Baass  13. TITLE  Director & Interim State Medicaid Director	P.O. Box 997413, MS 0000 Sacramento, CA 95899-7413	
14. DATE SUBMITTED December 13, 2023		
FOR CMS USE ONLY		
The state of the s	7. DATE APPROVED	
December 13, 2023	January 22, 2024	
PLAN APPROVED - ON		
18. EFFECTIVE DATE OF APPROVED MATERIAL  October 1, 2023	9. SIG OVING OFFICIAL Digitally signed by James G. Scott -S Date: 2024.01.22 17:45:02 -06'00'	
20. TYPED NAME OF APPROVING OFFICIAL 2	1. TITLE OF APPROVING OFFICIAL	
James G. Scott	Director, Division of Program Operations	
22. REMARKS	Sirector, Division of Frogram Operations	
Box 5: CMS pen and ink change to correct regulatory citation to 42  Boxes 7-8: CMS pen and ink change to add additional SPA page p		

Limitations on Attachment 3.1-A Page 14a

(Note: This chart is an overview only)

TYPE OF SERVICE	PROGRAM COVERAGE**	PRIOR AUTHORIZATION OR OTHER REQUIREMENTS*
pro pra as: En	Covered only when supplied by a pharmacy provider as prescribed by a physician, nurse practitioner, clinical nurse specialist, or physician assistant within the scope of his or her practice.  Enteral Formulae commonly used in providing SNF and ICF level of care is not separately billable.	Prior authorization is required for all products. Authorization is given when the enteral formulae is used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions that preclude the full use of regular food.
	Common household items (food) are not covered.	Dietary supplements or products that cannot be used as a complete source of nutrition are considered non-benefits, except that the program may deem such a product a benefit when it determines that the use of the product is neither investigational nor experimental when used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions.
**Coverage is limited to med	quired for emergency services. ically necessary services.	
TN No. <u>23-0044</u> Supersedes TN No. <u>20-0035</u>	Approval Date: <u>January 22, 2024</u>	Effective Date: October 1. 2023

Limitations on Attachment 3.1-B Page 14a

(Note: This chart is an overview only)

T)/DE OF OFD)//OF	TYPE OF SERVICE PROGRAM COVERAGE**	PRIOR AUTHORIZATION OR OTHER
TYPE OF SERVICE		REQUIREMENTS*
7c.3 Enteral Formulae	Covered only when supplied by a pharmacy provider as prescribed by a physician, nurse practitioner, clinical nurse specialist, or physician assistant within the scope of his or her practice.  Enteral Formulae commonly used in providing SNF and ICF level of care is not separately billable.	Prior authorization is required for all products. Authorization is given when the enteral formulae is used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions that preclude the full use of regular food.
	Common household items (food) are not covered.	Dietary supplements or products that cannot be used as a complete source of nutrition are considered non-benefits, except that the program may deem such a product a benefit when it determines that the use of the product is neither investigational nor experimental when used as a therapeutic regimen to prevent serious disability or death in patients with medically diagnosed conditions.

TN No. 23-0044 Supersedes TN No. <u>20-0035</u>

Approval Date: January 22, 2024 Effective Date: October 1, 2023

<sup>\*</sup>Prior authorization is not required for emergency services. \*\*Coverage is limited to medically necessary services.